These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 9711446)
21. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Shang CY; Pan YL; Lin HY; Huang LW; Gau SS J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447 [TBL] [Abstract][Full Text] [Related]
23. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]
24. [Attention-deficit/hyperactivity disorder. Clinical and treatment aspects]. Diaconu G; Grigore I; Burlea M Rev Med Chir Soc Med Nat Iasi; 2009; 113(3):656-62. PubMed ID: 20191811 [TBL] [Abstract][Full Text] [Related]
25. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. Dulcan M J Am Acad Child Adolesc Psychiatry; 1997 Oct; 36(10 Suppl):85S-121S. PubMed ID: 9334567 [TBL] [Abstract][Full Text] [Related]
26. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. Aman MG; Binder C; Turgay A J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL Neuropsychopharmacology; 1996 Feb; 14(2):125-37. PubMed ID: 8822535 [TBL] [Abstract][Full Text] [Related]
28. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068 [TBL] [Abstract][Full Text] [Related]
29. Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms. Kara T; Akaltun İ Clin Neuropharmacol; 2018; 41(1):28-30. PubMed ID: 29298167 [TBL] [Abstract][Full Text] [Related]
30. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Gibson AP; Bettinger TL; Patel NC; Crismon ML Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655 [TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample. Yang P; Hsu HY; Chiou SS; Chao MC Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272 [TBL] [Abstract][Full Text] [Related]
32. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. Firestone P; Musten LM; Pisterman S; Mercer J; Bennett S J Child Adolesc Psychopharmacol; 1998; 8(1):13-25. PubMed ID: 9639076 [TBL] [Abstract][Full Text] [Related]
33. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study. van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369 [TBL] [Abstract][Full Text] [Related]
34. Psychosocial treatments for attention-deficit/hyperactivity disorder in children. Barkley RA J Clin Psychiatry; 2002; 63 Suppl 12():36-43. PubMed ID: 12562060 [TBL] [Abstract][Full Text] [Related]
35. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Paterson R; Douglas C; Hallmayer J; Hagan M; Krupenia Z Aust N Z J Psychiatry; 1999 Aug; 33(4):494-502. PubMed ID: 10483843 [TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Spencer T; Biederman J; Wilens T; Harding M; O'Donnell D; Griffin S J Am Acad Child Adolesc Psychiatry; 1996 Apr; 35(4):409-32. PubMed ID: 8919704 [TBL] [Abstract][Full Text] [Related]
38. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder. Riggs PD; Thompson LL; Mikulich SK; Whitmore EA; Crowley TJ J Am Acad Child Adolesc Psychiatry; 1996 Aug; 35(8):1018-24. PubMed ID: 8755798 [TBL] [Abstract][Full Text] [Related]
39. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851 [TBL] [Abstract][Full Text] [Related]